Veru

VERU INC

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

S&P 500

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AKRO

ALLK

DADA

ELAB

VERU

S&amp;P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher

Wall Street_Dow

Dow Edges Higher; AT&amp;T Posts Upbeat Earnings

bz_pharma_briefs

Biotech

Health Care

Movers

General

Veru&#39;s enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.

Veru Shares Tumble Despite Enobosarm&#39;s Lean Muscle Preservation Breakthrough

Veru Inc

VERUS INTL INC by Verus International, Inc.

Verus International Inc

VerusCoin

Press Releases

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Veru Participates in a Virtual Investor KOL Connect Segment

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

Assertio Holdings

Biote

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

China Pharma Holding

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Ikena Oncology

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Nutriband

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Cassava Sciences

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ventyx Biosciences

HC Wainwright & Co.

Oppenheimer

B. Riley Securities

Raymond James

Jefferies

Comments

Veru

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell